AstraZeneca's Etcamah Fails Key Breast Cancer Trial

1 Minute Read Listen to Article

Sep 12, 2026 15:15

AstraZeneca's Etcamah (camizestrant) did not meet its primary goal in the Phase III SERENA-4 trial for advanced breast cancer, despite numerical improvement.

AstraZeneca's Etcamah Fails Key Breast Cancer Trial

Photograph: ANI Photo

Key Points

AstraZeneca's Etcamah failed its primary goal in the Phase III SERENA-4 trial for advanced breast cancer.
The drug, combined with palbociclib, did not show statistically significant improvement in progression-free survival.
A numerical improvement was observed in first-line treatment, and no new safety concerns were identified.
AstraZeneca remains confident in Etcamah's potential and is evaluating it in other early breast cancer trials.

New Delhi, Sep 12 (PTI) Biopharmaceutical major AstraZeneca has said its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib did not meet its objective of statistically significant improvement in progression-free survival in patients with advanced breast cancer.

However, a numerical improvement was observed in the first-line treatment of patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer who had not received any systemic treatment for advanced disease, the company said in a statement.

The SERENA-4 trial evaluated the Etcamah and palbociclib combination versus an aromatase inhibitor (anastrozole) combined with palbociclib. Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor.

Regarding the drug's safety, the company noted that the safety profile of Etcamah in combination with palbociclib was consistent with the known profiles of each medicine, with no new safety concerns identified.

"Whilst we are disappointed by the SERENA-4 outcome, it sharpens our focus on maximising the number of patients who can benefit from Etcamah today based on SERENA-6 and reinforces the importance of ESR1 testing for patients on first-line therapy," said Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca.

Galbraith added that early breast cancer represents an important opportunity, and the company remains confident in the long-term potential of the drug.

AstraZeneca stated that Etcamah is also currently being evaluated in early breast cancer through the CAMBRIA-1 and CAMBRIA-2 Phase III trials, encompassing approximately 10,000 patients at intermediate and high risk of recurrence in the adjuvant setting.

Source: PTI By Rediff Money Desk, New Delhi

DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.